PHENPROCOUMON

/static/temp/default.svg

Search structure


Trade Names	LIQUAMAR
Synonyms	BS-7565 Fencumar Liquamar Marcoumar Marcumar Phenprocoumarol Phenprocoumarole Phenprocoumon Phenprocumone RO-1-4849
Status
Molecule Category	UNKNOWN
ATC	B01AA04
UNII	Q08SIO485D
EPA CompTox	DTXSID5023459


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DQDAYGNAKTZFIW-UHFFFAOYSA-N
Smiles	CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O
InChI	InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H16O3
Molecular Weight	280.32
AlogP	4.04
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	50.44
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	21.0

Pharmacology

Mechanism of Action	Action	Reference
Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	INHIBITOR	PubMed Wikipedia


Protein: Vitamin k epoxide reductase complex subunit 1 isoform 1 Description: Vitamin K epoxide reductase complex subunit 1 Organism : Homo sapiens Q9BQB6 ENSG00000167397

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	-	-	200	-
Enzyme Protease Aspartic protease Aspartic protease AA clan Aspartic protease A2A subfamily	-	1000	-	1-1000	-

Assay Description	Organism	Bioactivity	Reference
Binding affinity against HIV-1 protease	Human immunodeficiency virus 1	0.8 nM
Binding affinity towards HIV protease was determined	None	800.0 nM
Inhibition of VKORC1 in rat liver microsomes in presence of 0.003 to 0.2 mM vitamin K	Rattus norvegicus	200.0 nM

Related Entries

Cross References

Resources	Reference
ChEBI	50438
ChEMBL	CHEMBL1465
DrugBank	DB00946
DrugCentral	2138
FDA SRS	Q08SIO485D
Human Metabolome Database	HMDB0015081
Guide to Pharmacology	6839
KEGG	D05457
PubChem	54680692
SureChEMBL	SCHEMBL43031
ZINC	ZINC03876174

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).